Recruiting

Comparison of Remimazolam and Propofol in Endoscopic Examinations and Treatments

This study aims to evaluate the efficacy and safety of Remimazolam, either used alone or in combination with Propofol, for moderate sedation anesthesia during endoscopic therapies or examinations. Additionally, it seeks to explore whether their combination can further enhance the quality of patient anesthesia and recovery outcomes.

ClinicalTrials.gov IDNCT06777758

PhasePHASE4

Enrollment90

SponsorKaohsiung Veterans General Hospital.

Age20 Years

SexALL

I'm interested View official listing

Conditions studied

Postoperative Complications, Respiratory Depression, Postoperative Nausea, Vomiting, Constipation

About this study

Interventions

Drug: Remimazolam — Remimazolam
Drug: Propofol — Propofol dose reduction ratio

Primary outcomes

Dose change (Perioperatively (during upper gastrointestinal endoscopy))

Eligibility information

Inclusion Criteria: * Subjects are between 20-80 years old. * Anesthesiologists rated ASA as between I and III. * Patients undergoing upper gastrointestinal endoscopic examination or therapy. Exclusion Criteria: * Allergy to Propofol, Remimazolam, or opioid medications. * Emergency surgery. * Pregnancy. * History of malignant hyperthermia. * Impaired liver or kidney function. * Airway difficulties due to pharyngeal tumors. * Refusal to participate.

Study locations

Kaohsiung Veterans General Hospital, Kaohsiung City, 81362 Taiwan

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-30.